Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Treatment with evolocumab (Repatha), a common PCSK9 inhibitor, can help patients with a history of percutaneous coronary intervention (PCI) lower their risk of a major cardiovascular event, according to new findings published in Circulation: Cardiovascular Interventions.[1] “Patients who have undergone PCI...

  • 123456 Profile photo of Madelyn

    My patients ask about outcome data with PCSK9 inhibitors, is it worth it? Good to see more.